公开(公告)号：US11913023B2

公开(公告)日：2024-02-27

申请号：US17465759

申请日：2021-09-02

申请人： Walking Fish Therapeutics

发明人： Kathleen Boyle ,  Hangil Park ,  Srinivas Kothakota ,  Mark Selby ,  Thomas Brennan ,  Lewis T. Williams

IPC分类号： C12N5/0781 ,  A61K35/17 ,  C07K16/30

CPC分类号： C12N5/0635 ,  A61K35/17 ,  C07K16/303 ,  C07K16/3069 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/03 ,  C12N2510/00

摘要： The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

公开(公告)号：US20240002793A1

公开(公告)日：2024-01-04

申请号：US18314778

申请日：2023-05-09

申请人： Walking Fish Therapeutics

发明人： Kathleen Boyle ,  Hangil Park ,  Srinivas Kothakota ,  Mark Selby ,  Thomas Brennan ,  Lewis T. Williams

IPC分类号： C12N5/0781 ,  A61K35/17 ,  C07K16/30

CPC分类号： C12N5/0635 ,  A61K35/17 ,  C07K16/303 ,  C07K16/3069 ,  C07K2317/53 ,  C07K2319/03 ,  C12N2510/00 ,  C07K2317/622

摘要： The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

公开(公告)号：US20240034995A1

公开(公告)日：2024-02-01

申请号：US18316198

申请日：2023-05-11

申请人： Walking Fish Therapeutics

发明人： Kathleen Boyle ,  Hangil Park ,  Srinivas Kothakota ,  Mark Selby ,  Thomas Brennan ,  Lewis T. Williams

IPC分类号： C12N5/0781 ,  A61K35/17 ,  C07K16/30

CPC分类号： C12N5/0635 ,  A61K35/17 ,  C07K16/303 ,  C07K16/3069 ,  C07K2317/53 ,  C07K2319/03 ,  C12N2510/00 ,  C07K2317/622

摘要： The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

公开(公告)号：US12037604B2

公开(公告)日：2024-07-16

申请号：US18316198

申请日：2023-05-11

申请人： Walking Fish Therapeutics

发明人： Kathleen Boyle ,  Hangil Park ,  Srinivas Kothakota ,  Mark Selby ,  Thomas Brennan ,  Lewis T. Williams

IPC分类号： C12N5/0781 ,  A61K35/17 ,  C07K16/30

CPC分类号： C12N5/0635 ,  A61K35/17 ,  C07K16/303 ,  C07K16/3069 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/03 ,  C12N2510/00

摘要： The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

公开(公告)号：US20220073876A1

公开(公告)日：2022-03-10

申请号：US17465759

申请日：2021-09-02

申请人： Walking Fish Therapeutics

发明人： Kathleen Boyle ,  Hangil Park ,  Srinivas Kothakota ,  Mark Selby ,  Thomas Brennan ,  Lewis T. Williams

IPC分类号： C12N5/0781 ,  A61K35/17 ,  C07K16/30

摘要： The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.